Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
29 May 2025
With Gerald Posner
youth-gender-medicine
Gerald Posner — Pulitzer finalist, former lawyer, and veteran pharmaceutical investigator — brings a forensic perspective to the trans medical industry that mainstream journalism has largely avoided. Drawing explicit parallels to the opioid crisis, he identifies a familiar structure: off-label prescribing, regulatory blind spots, suppressed dissent, and financial incentives that favour creating long-term patients over restoring health. WPATH's internal communications reveal political interference in clinical guidance that presents itself as settled science. The episode asks what happens when the institutions meant to protect children — medical, regulatory, journalistic — are themselves captured.
Gerald Posner is a Pulitzer Prize finalist, former lawyer, and veteran investigative journalist who has spent decades tracing how pharmaceutical companies shape medical practice to serve commercial ends. When someone with that record turns his attention to the trans medical industry, the implications are difficult to dismiss. His conversation on Beyond Gender brings a forensic lens to a story that has largely evaded the kind of serious investigative scrutiny it warrants. Posner's central argument draws on what he has observed across years of pharmaceutical reporting: the same playbook that produced the opioid crisis is now visible in the expansion of puberty blockers and cross-sex hormones for minors. Off-label prescribing, regulatory gaps, and a selectively promoted research base — while dissenting voices are sidelined — are patterns he recognises. What is distinctive in this case is the ideological layer that has made the commercial logic almost uniquely difficult to challenge publicly. The episode is candid about how mainstream journalism has failed to investigate these dynamics. Posner describes being shut out by publishers and the broader pattern of editorial reluctance — outlets unwilling to run stories that could bring institutional consequences. Advocacy organisations, he suggests, have played a significant role in determining what gets covered, what framing gets applied, and what disappears quietly. The result is a media environment in which some of the most significant questions about a medical intervention affecting children have gone largely unanswered. WPATH — the World Professional Association for Transgender Health — comes under sustained scrutiny. Its internal communications, Posner argues, show political considerations shaping clinical guidance that presents itself as scientific consensus. This matters because standards of care derive their authority from the assumption that they are produced through rigorous, disinterested processes. When that assumption cannot be sustained, the clinical guidance built on it cannot be taken at face value. The FDA loophole allowing off-label prescribing to expand without standard drug-approval scrutiny is part of the same structural picture. What makes this episode significant is the perspective Posner brings. He is not approaching the subject as a cultural commentator but as someone who has documented, in detail, how pharmaceutical industries manufacture consent, suppress inconvenient findings, and create long-term patient populations as a revenue strategy. His observation that we may be building a generation of patients for life — through interventions initiated in childhood and requiring lifelong medical management — is not speculation. It is a hypothesis drawn from a pattern he has seen before. The opioid crisis produced its warnings early and its reckoning late. This episode is an argument that the institutions meant to prevent that outcome are, in this case, once again failing to perform that function.
